NCCN now lists the brain-penetrant ROS1 inhibitor after progression on earlier TKIs, including as a preferred option for ...

Data presented at ESMO Congress 2026 show lifileucel met its feasibility end point in refractory sarcoma, with 80% disease ...

Fewer than two-thirds of patients prescribed augmentation begin infusions, and half of starters miss doses. Structured ...

Telehealth surpasses out-of-state travel for abortion care in total-ban states in 2025, and a second study suggests telehealth and clinic patients differ.

UAB experts said new bladder cancer, myeloma, and lung cancer therapies are changing care, but access and costs remain barriers.

Single-discipline autism guidelines that fail Institute of Medicine standards risk omitting critical developmental domains, potentially distorting care coverage and clinical decisions for children ...

Curran urges clinicians to treat ALL treatment guidance as a baseline and, when resources are limited, to focus on what ...

Three experts apply policy, pharmacy operations, and member-level lenses to the same prescriptions to show why cost at the ...

Katelyn B. Meyer, PharmD, discusses how payers can prepare for emerging specialty therapies, from cell and gene therapies to ...

Most Medicaid enrollees who lost coverage during the unwinding were removed for procedural reasons, and expansion adults will ...

Approximately 4.3 million Medicare beneficiaries will have their plans terminated at the end of 2026—including 3.1 million ...

Among patients with essential thrombocythemia, higher average ropeginterferon alfa-2b exposure was associated with greater JAK2V617F allele burden reduction at 6 or 7 months (P = .021).